ThirdLaw Molecular
ThirdLaw Molecular LLC (branded online as Ladder Bio) is a drug-discovery and diagnostics company founded in 2020 to develop a novel class of chemically synthesized, structured oligomeric macromolecules for targeted therapeutics and diagnostic reagents. The organization designs and synthesizes large combinatorial libraries (including DNA-encoded libraries), applies computational molecular design and high-throughput screening to identify protein binders, and pursues research collaborations and scale-up manufacturing for candidate discovery. The company maintains policies and processes for PHS-funded research compliance.
Industries
Nr. of Employees
small (1-50)
ThirdLaw Molecular
Blue Bell, Pennsylvania, United States, North America
Products
4.5-billion-member DNA-encoded library of structured synthetic macromolecules
A large DNA-encoded combinatorial library composed of chemically synthesized, structured fused-ring oligomer macromolecules designed for screening against protein targets.
4.5-billion-member DNA-encoded library of structured synthetic macromolecules
A large DNA-encoded combinatorial library composed of chemically synthesized, structured fused-ring oligomer macromolecules designed for screening against protein targets.
Services
Collaborative discovery and optimization partnerships
Research collaborations with pharmaceutical and biotech organizations to discover and optimize selective synthetic macromolecule binders for target proteins.
DNA-encoded library screening and hit identification
DEL screening workflows and hit validation services to identify protein-binding candidates from multi-billion-member libraries.
Diagnostic reagent and multiplex assay development
Development of synthetic binding reagents and multiplex assay formats intended for point-of-care and at-home diagnostic applications.
Collaborative discovery and optimization partnerships
Research collaborations with pharmaceutical and biotech organizations to discover and optimize selective synthetic macromolecule binders for target proteins.
DNA-encoded library screening and hit identification
DEL screening workflows and hit validation services to identify protein-binding candidates from multi-billion-member libraries.
Diagnostic reagent and multiplex assay development
Development of synthetic binding reagents and multiplex assay formats intended for point-of-care and at-home diagnostic applications.
Expertise Areas
- Targeted drug discovery using synthetic macromolecules
- DNA-encoded library (DEL) construction and screening
- Combinatorial library synthesis and scale-up
- Diagnostic reagent and multiplex assay development
Key Technologies
- Structured fused-ring synthetic oligomer macromolecules
- DNA-encoded libraries (DEL)
- High-throughput screening (HTS)
- Computational molecular design